“期刊投稿智能支持系统(JSAS)”测试版开通

2010-02-05 MedSci原创 MedSci原创

文章投稿选择什么杂志,一直是大家的难题,许多用户,只知道自己熟悉的十来种杂志,投稿的选择面非常窄。应广大用户的要求,MedSci技术人员,日夜攻关,继影响因子,投稿建议和杂志主页系统(http://www.medsci.cn/sci/)上线后,再次上线一个重大项目:期刊投稿智能支持系统(Journal selection-assisted system, JS

    文章投稿选择什么杂志,一直是大家的难题,许多用户,只知道自己熟悉的十来种杂志,投稿的选择面非常窄。应广大用户的要求,MedSci技术人员,日夜攻关,继影响因子,投稿建议和杂志主页系统(https://www.medsci.cn/sci/)上线后,再次上线一个重大项目:期刊投稿智能支持系统(Journal selection-assisted system, JSASTM β版),这是目前中国唯一的智能选择杂志辅助系统。

    这套系统与国外同类产品,以及与其它系统均不同,具有以下特征:

  • 目标杂志全部是SCI杂志,不包括非SCI杂志!让您的选择更精准!
  • 支持模糊搜索,自动进行推荐杂志排序,并给出推荐度。
  • 并实时显示杂志的国际影响力,方便您根据文章的质量,内容进行有针对性选择。
  • 同时提供杂志介绍,以及Eigenfactor链接(仅供非常专业用户参考),例文参考等。

    当然,目前仅是测试版阶段,因此,只允许注册用户免费使用。今后我们全面完善该系统,再考虑开放给用户使用。 

    测试并使用地址https://www.medsci.cn/sci/jsas.do

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=10159, encodeId=2c0310159ad, content=非常不错,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 16:13:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10137, encodeId=dae71013e1a, content=非常好,应该早来贵网站看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 15:20:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103, encodeId=25d3210319, content=QSAR HIV Iintegrase inhibitors, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=499e34954, createdName=zhangsherry, createdTime=Thu Mar 31 12:07:00 CST 2011, time=2011-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704010, encodeId=85f11e0401097, content=<a href='/topic/show?id=cb9660e9663' target=_blank style='color:#2F92EE;'>#期刊投稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60796, encryptionId=cb9660e9663, topicName=期刊投稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162930619596, createdName=yangcx0925, createdTime=Tue Nov 23 17:40:00 CST 2010, time=2010-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007724, encodeId=655b200e72456, content=<a href='/topic/show?id=cf4d1590956' target=_blank style='color:#2F92EE;'>#SAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15909, encryptionId=cf4d1590956, topicName=SAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 26 19:40:00 CST 2010, time=2010-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017, encodeId=b4d2101e2d, content=非常实用, 解决了疑难, 节省了时间, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=flowerinwater, createdTime=Fri Feb 19 10:14:00 CST 2010, time=2010-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013, encodeId=15d010137d, content=真好用, 谢谢medsci, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=life, createdTime=Wed Feb 10 18:22:00 CST 2010, time=2010-02-10, status=1, ipAttribution=)]
    2014-06-29 lidage

    非常不错,谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=10159, encodeId=2c0310159ad, content=非常不错,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 16:13:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10137, encodeId=dae71013e1a, content=非常好,应该早来贵网站看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 15:20:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103, encodeId=25d3210319, content=QSAR HIV Iintegrase inhibitors, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=499e34954, createdName=zhangsherry, createdTime=Thu Mar 31 12:07:00 CST 2011, time=2011-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704010, encodeId=85f11e0401097, content=<a href='/topic/show?id=cb9660e9663' target=_blank style='color:#2F92EE;'>#期刊投稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60796, encryptionId=cb9660e9663, topicName=期刊投稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162930619596, createdName=yangcx0925, createdTime=Tue Nov 23 17:40:00 CST 2010, time=2010-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007724, encodeId=655b200e72456, content=<a href='/topic/show?id=cf4d1590956' target=_blank style='color:#2F92EE;'>#SAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15909, encryptionId=cf4d1590956, topicName=SAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 26 19:40:00 CST 2010, time=2010-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017, encodeId=b4d2101e2d, content=非常实用, 解决了疑难, 节省了时间, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=flowerinwater, createdTime=Fri Feb 19 10:14:00 CST 2010, time=2010-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013, encodeId=15d010137d, content=真好用, 谢谢medsci, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=life, createdTime=Wed Feb 10 18:22:00 CST 2010, time=2010-02-10, status=1, ipAttribution=)]
    2014-06-29 lidage

    非常好,应该早来贵网站看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=10159, encodeId=2c0310159ad, content=非常不错,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 16:13:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10137, encodeId=dae71013e1a, content=非常好,应该早来贵网站看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 15:20:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103, encodeId=25d3210319, content=QSAR HIV Iintegrase inhibitors, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=499e34954, createdName=zhangsherry, createdTime=Thu Mar 31 12:07:00 CST 2011, time=2011-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704010, encodeId=85f11e0401097, content=<a href='/topic/show?id=cb9660e9663' target=_blank style='color:#2F92EE;'>#期刊投稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60796, encryptionId=cb9660e9663, topicName=期刊投稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162930619596, createdName=yangcx0925, createdTime=Tue Nov 23 17:40:00 CST 2010, time=2010-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007724, encodeId=655b200e72456, content=<a href='/topic/show?id=cf4d1590956' target=_blank style='color:#2F92EE;'>#SAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15909, encryptionId=cf4d1590956, topicName=SAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 26 19:40:00 CST 2010, time=2010-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017, encodeId=b4d2101e2d, content=非常实用, 解决了疑难, 节省了时间, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=flowerinwater, createdTime=Fri Feb 19 10:14:00 CST 2010, time=2010-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013, encodeId=15d010137d, content=真好用, 谢谢medsci, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=life, createdTime=Wed Feb 10 18:22:00 CST 2010, time=2010-02-10, status=1, ipAttribution=)]
    2011-03-31 zhangsherry

    QSAR HIV Iintegrase inhibitors

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=10159, encodeId=2c0310159ad, content=非常不错,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 16:13:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10137, encodeId=dae71013e1a, content=非常好,应该早来贵网站看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 15:20:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103, encodeId=25d3210319, content=QSAR HIV Iintegrase inhibitors, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=499e34954, createdName=zhangsherry, createdTime=Thu Mar 31 12:07:00 CST 2011, time=2011-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704010, encodeId=85f11e0401097, content=<a href='/topic/show?id=cb9660e9663' target=_blank style='color:#2F92EE;'>#期刊投稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60796, encryptionId=cb9660e9663, topicName=期刊投稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162930619596, createdName=yangcx0925, createdTime=Tue Nov 23 17:40:00 CST 2010, time=2010-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007724, encodeId=655b200e72456, content=<a href='/topic/show?id=cf4d1590956' target=_blank style='color:#2F92EE;'>#SAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15909, encryptionId=cf4d1590956, topicName=SAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 26 19:40:00 CST 2010, time=2010-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017, encodeId=b4d2101e2d, content=非常实用, 解决了疑难, 节省了时间, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=flowerinwater, createdTime=Fri Feb 19 10:14:00 CST 2010, time=2010-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013, encodeId=15d010137d, content=真好用, 谢谢medsci, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=life, createdTime=Wed Feb 10 18:22:00 CST 2010, time=2010-02-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=10159, encodeId=2c0310159ad, content=非常不错,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 16:13:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10137, encodeId=dae71013e1a, content=非常好,应该早来贵网站看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 15:20:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103, encodeId=25d3210319, content=QSAR HIV Iintegrase inhibitors, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=499e34954, createdName=zhangsherry, createdTime=Thu Mar 31 12:07:00 CST 2011, time=2011-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704010, encodeId=85f11e0401097, content=<a href='/topic/show?id=cb9660e9663' target=_blank style='color:#2F92EE;'>#期刊投稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60796, encryptionId=cb9660e9663, topicName=期刊投稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162930619596, createdName=yangcx0925, createdTime=Tue Nov 23 17:40:00 CST 2010, time=2010-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007724, encodeId=655b200e72456, content=<a href='/topic/show?id=cf4d1590956' target=_blank style='color:#2F92EE;'>#SAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15909, encryptionId=cf4d1590956, topicName=SAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 26 19:40:00 CST 2010, time=2010-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017, encodeId=b4d2101e2d, content=非常实用, 解决了疑难, 节省了时间, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=flowerinwater, createdTime=Fri Feb 19 10:14:00 CST 2010, time=2010-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013, encodeId=15d010137d, content=真好用, 谢谢medsci, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=life, createdTime=Wed Feb 10 18:22:00 CST 2010, time=2010-02-10, status=1, ipAttribution=)]
    2010-10-26 jiyangfei
  6. [GetPortalCommentsPageByObjectIdResponse(id=10159, encodeId=2c0310159ad, content=非常不错,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 16:13:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10137, encodeId=dae71013e1a, content=非常好,应该早来贵网站看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 15:20:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103, encodeId=25d3210319, content=QSAR HIV Iintegrase inhibitors, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=499e34954, createdName=zhangsherry, createdTime=Thu Mar 31 12:07:00 CST 2011, time=2011-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704010, encodeId=85f11e0401097, content=<a href='/topic/show?id=cb9660e9663' target=_blank style='color:#2F92EE;'>#期刊投稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60796, encryptionId=cb9660e9663, topicName=期刊投稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162930619596, createdName=yangcx0925, createdTime=Tue Nov 23 17:40:00 CST 2010, time=2010-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007724, encodeId=655b200e72456, content=<a href='/topic/show?id=cf4d1590956' target=_blank style='color:#2F92EE;'>#SAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15909, encryptionId=cf4d1590956, topicName=SAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 26 19:40:00 CST 2010, time=2010-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017, encodeId=b4d2101e2d, content=非常实用, 解决了疑难, 节省了时间, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=flowerinwater, createdTime=Fri Feb 19 10:14:00 CST 2010, time=2010-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013, encodeId=15d010137d, content=真好用, 谢谢medsci, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=life, createdTime=Wed Feb 10 18:22:00 CST 2010, time=2010-02-10, status=1, ipAttribution=)]
    2010-02-19 flowerinwater

    非常实用, 解决了疑难, 节省了时间

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=10159, encodeId=2c0310159ad, content=非常不错,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 16:13:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10137, encodeId=dae71013e1a, content=非常好,应该早来贵网站看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a03104789, createdName=lidage, createdTime=Sun Jun 29 15:20:00 CST 2014, time=2014-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103, encodeId=25d3210319, content=QSAR HIV Iintegrase inhibitors, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=499e34954, createdName=zhangsherry, createdTime=Thu Mar 31 12:07:00 CST 2011, time=2011-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704010, encodeId=85f11e0401097, content=<a href='/topic/show?id=cb9660e9663' target=_blank style='color:#2F92EE;'>#期刊投稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60796, encryptionId=cb9660e9663, topicName=期刊投稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=162930619596, createdName=yangcx0925, createdTime=Tue Nov 23 17:40:00 CST 2010, time=2010-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007724, encodeId=655b200e72456, content=<a href='/topic/show?id=cf4d1590956' target=_blank style='color:#2F92EE;'>#SAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15909, encryptionId=cf4d1590956, topicName=SAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Oct 26 19:40:00 CST 2010, time=2010-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1017, encodeId=b4d2101e2d, content=非常实用, 解决了疑难, 节省了时间, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=flowerinwater, createdTime=Fri Feb 19 10:14:00 CST 2010, time=2010-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013, encodeId=15d010137d, content=真好用, 谢谢medsci, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=life, createdTime=Wed Feb 10 18:22:00 CST 2010, time=2010-02-10, status=1, ipAttribution=)]
    2010-02-10 life

    真好用, 谢谢medsci

    0

相关资讯

SSCI是什么?它的期刊目录有哪些?

注意:SSCI不是SCI,它是社会科学的SCI。 SSCI影响因子查询,可以参考 http://www.medsci.cn/sci/ssci.asp 当然,如果您在知名的大学的话,可以到ISI上直接查询:http://www.thomsonreuters.com/ 以下内容由万跃华教授整理: 社会科学引文索引(Social Sciences Citation Index,简称SS

SCI/EI/SSCI/CSSCI/A&HCI/ISTP详解

什么是SCI? SCI是美国《科学引文索引》的英文简称,其全称为:Science Citation Index,,创刊于1961年,它是根据现代情报学家加菲尔德(Engene Garfield) 1953年提出的引文思想而创立的。时至今日加菲尔德仍是SCI主编之一。SCI是由 ISI( Institute for Scientifi

为什么前两天投稿后,今天网站打不开了呢?

偶尔客户碰到刚刚投过稿的杂志,过两天网站打不开了,或打开的根本不是这个杂志。有些作者通过我们的影响因子查询系统(提供了各个杂志的主页)的主页链接,打开一看,竟然也不是这个杂志,所以很迷惑。 我们总结了原因,大多是因为该杂志往往域名管理不当,或续费不及时,结果域名被一些不法网站抢注了,导致无法打开!一旦碰到类似情况,可以发邮件给主编,或等待一周左右时间,杂志如果域名仍然能续费的话,则网站能继续开通

英文论文写作、投稿过程中的注意事项

英文论文写作、投稿过程中的注意事项 tangdl2000的个人经验【写作前准备】 1、自己的实验结果是否够发一篇SCI文章?2、适合发表在什么杂志?是选择专业期刊?还是综合期刊?3、为什么类型的投稿(Types of submission)?比如Articles(论著);Reviews(综述);Reports(报告);Letter to editor(来信)等。4、该杂志的影响因子(Impac

MedSci面向大中华区用户首推MedSci指数

MedSci一直致力于推广科研教育和培训活动。除了向您免费提供大量关于sci写作的资源外,我们还通过会议报告、专业培训班、邮件及网站宣传等诸多形式丰富您对sci论文写作的认识。MedSci发展的理念是改善并提高母语非英语人士,尤其是中国临床和科研工作者的科研论文语言表达质量,节约他们宝贵的科研时间。 但是我们知道,大量的科研人员在选择合适的投稿杂志时,会遇到重重困难。往往只能凭借一知半点的经验

SCI文章投稿经验技巧(MedSci)

SCI论文的关键点 SCI文章对于我们每个人来说,都非常重要。那么一篇文章能不能发表SCI杂志,有哪些关键点?MedSci总结有几个关键性环节: 1、首先当然是文章的设计,MedSci编辑经常发现作者递送过来的文章一个重要的问题就是设计存在缺陷,不是分组缺少,就是样本量过低,或缺少对照,或各部分实验逻辑性不强,这些致命性缺陷是困扰许多作者的关键问题。 2